Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy Volunteers

A Phase I, Open-label, Single-dose, Single-Period Study to Evaluate the Pharmacokinetics of Mucinex® 600 mg Extended-Release Bi-layer Tablet in Normal Healthy Subjects.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03644108

Enrollment

Registered

2018-08-23

Start date

2009-06-04

Completion date

2009-06-15

Last updated

2019-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

Evaluate the Pharmacokinetics of Mucinex® 600 mg Extended-Release Bi-Layer Tablet in Normal Healthy Subjects

Interventions

DRUGMucinex® ER 600 mg

Single dose of Mucinex® 600 mg ER Bi-Layer tablet

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. Males and/or females between the ages of 19 and 55 years, inclusive. 2. Females of childbearing potential must have been using 1 of the following acceptable birth control methods: 1. Intra-uterine device (IUD) in place for at least 3 months prior to Day 1 through 30 days beyond study completion or first menstrual period. 2. Barrier method (condom or diaphragm) with spermicide for at least 7 days prior to screening through 30 days beyond study completion or first menstrual period (whichever is longer). 3. Stable hormonal contraceptive (e.g., PO, depo injection, transdermal patch, or vaginal ring) for at least 3 months prior to Day 1 through 30 days beyond completion of study or first menstrual period. Note: Abstinence is not an acceptable form of contraception; however, abstinent female subjects may have been admitted to the study if they agreed, and signed a statement to the effect, that upon becoming sexually active, would use a condom with spermicide from screening through 30 days beyond completion of the study. 3. Females of non-childbearing potential must have been surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to Day 1 or hysterectomy and/or bilateral oophorectomy at least 3 months prior to Day 1) or postmenopausal \>2 years prior to Day 1. A follicle stimulating hormone (FSH) level \>40 miU/mL must be obtained and recorded for any postmenopausal females. 4. Good general health as determined by the PI's review of medical history, physical examination, vital sign measurements, electrocardiogram (ECG), and clinical laboratory measures. 5. Within 15% of ideal body weight (Table of 'Desirable Weights of Adults' Metropolitan Life Insurance Company, 1983). 6. Non-tobacco users, who had not used nicotine or nicotine-containing products for at least 365 days prior to Day 1. 7. Able to read, understand, and sign the informed consent form (ICF), after the nature of the study had been explained. 8. Negative urine screen for drugs of abuse and alcohol at screening and each check-in. 9. If female, negative finding on serum pregnancy test at screening and each check-in.

Exclusion criteria

1. Clinically significant abnormalities detected by medical history, physical examination, vital sign measurements, ECG, or clinical laboratory findings (as determined by the PI/designee) including a hemoglobin value \<12 g/dL at screening. If a subject's hemoglobin drops below 11.0 g/dL during the study, the subject may be dropped from the study at the discretion of the PI. 2. Any disease or condition that could impact absorption, distribution, metabolism, or elimination of the study drugs (as determined by the PI/designee). 3. Alcoholism or medicinal product or drug abuse within the past 2 years or excessive alcohol consumption (more than 10 units per week) (1 unit is defined as 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of spirits (i.e., 'hard' liquor such as gin, whiskey, or vodka, et. al.). The subject could not experience tolerance, withdrawal, compulsive use, or substance related problems such as medical complications, disruption in social and family relationships, vocational or financial difficulties, or legal problems. 4. Females who were pregnant or nursing. 5. History of hypersensitivity reaction to guaifenesin. 6. Receipt of an investigational drug within 30 days prior to Day 1. 7. Abnormal diet (for whatever reason) during the 30 days prior to Day 1. 8. Donation of blood or significant loss of blood within 56 days or plasma within 14 days prior to Day 1. 9. Known or suspected use of illicit drugs. 10. The use of any medication (with the exception of hormonal contraceptives for women of childbearing potential) for 14 days or 5 half-lives of the drug (whichever is longer) prior to Day 1. 11. Test positive for Hepatitis B surface antigen, Hepatitis C antibodies, or human immunodeficiency virus (HIV).

Design outcomes

Primary

Measure	Time frame	Description
Maximum Observed Plasma Concentration (Cmax) of Guaifenesin	0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2	Pharmacokinetic Parameters Cmax (Maximum observed drug concentration)
Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin	0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2	Area under the drug concentration-time curve calculated using linear trapezoidal summation from time zero to time t, where t is the time of the last measurable concentration (Ct).
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC(0-inf)) of Guaifenesin	0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2	Area under the drug concentration-time curve from time zero to infinity, AUC(0-inf) = AUC(0-t) + Ct/Kel, where Kel is the terminal elimination rate constant.
Time to Maximum Observed Concentration (Tmax) of Guaifenesin	0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2	Pharmacokinetic Parameter tmax (Time of the maximum observed drug concentration).
Area Under Plasma Concentration Curve Ratio (AUCR) of Guaifenesin	0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2	Ratio of AUC(0-t) to AUC(0-inf), referred to as AUCR. \[AUCR = AUC(0-t) / AUC(0-inf)\]
Apparent Terminal Elimination Rate Constant (Kel) of Guaifenesin	0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2	Apparent terminal elimination rate constant (Kel) calculated by linear regression of the terminal linear portion of the log concentration-time curve.
Apparent Terminal Elimination Half-life (t1/2) of Guaifenesin	0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2	Apparent terminal elimination half-life (t1/2) calculated as ln(2)/Kel.

Secondary

Measure	Time frame	Description
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)	Up to Day 2	Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied. Mild = AE did not limit usual activities; subject may have experienced slight discomfort. Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort. Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain. Relationship to Investigational Medicinal Products (IMP) Unlikely = Slight, but remote, chance that AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP. Probable = Most likely that AE was caused by IMP.

Participant flow

Recruitment details

This was a single-centre study.

Pre-assignment details

A total of 30 subjects were screened for the study; All 30 subjects were included single-period.

Participants by arm

Arm	Count
Mucinex® 600 mg ER Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.	30
Total	30

Baseline characteristics

Characteristic	Mucinex® 600 mg ER
Age, Continuous	26.3 years STANDARD_DEVIATION 6.97
Body Mass Index	23.976 kg/m^2 STANDARD_DEVIATION 1.8368
Height	68.41 in STANDARD_DEVIATION 3.222
Race Asian	1 Participants
Race Black	2 Participants
Race Caucasian	27 Participants
Sex: Female, Male Female	15 Participants
Sex: Female, Male Male	15 Participants
Weight	160.4 lb STANDARD_DEVIATION 23.11

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	5 / 30
other Total, other adverse events	5 / 30
serious Total, serious adverse events	0 / 30